Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
Year: 2024
Type: article
Source: Annals of Oncology
Institutions: Centre Hospitalier Universitaire Vaudois, Peter MacCallum Cancer Centre, Université Paris-Saclay, Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Trinity College Dublin, St. James's Hospital, Dana-Farber Cancer Institute, Aberdeen Royal Infirmary, European Institute of Oncology, Centre Léon Bérard, Leiden University Medical Center, Cancer Research UK, University College London, International Breast Cancer Study Group
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Breast Cancer Research Foundation, Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Wellcome Trust, Francis Crick Institute, Mark Foundation For Cancer Research, BeiGene, Cancer Research UK, National Institute for Health and Care Research, University College London, European Commission, Rosetrees Trust, National Breast Cancer Foundation, Ipsen, Genentech, Foundation Medicine, Medical Research Council
OpenAlex ID: W4394989609